MDRNA Inks Early-Stage Research Deal with Pfizer | GenomeWeb

MDRNA announced this week that it has begun a research study with Pfizer focused on RNAi drug discovery.

Under the deal, MDRNA will formulate Pfizer's oligonucleotides in its proprietary di-alkylated amino acids, or DiLA2, delivery vehicles for in vivo evaluation by the drugs giant. MDRNA will also design and synthesize UsiRNAs, duplex RNAs containing at least one non-nucleotide monomer, against Pfizer-specified targets.

Additional terms were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.